Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 18226 participants.

Also called NCT03473223

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 18,226 participants (enrolled count) (from the registry)
Sponsor
  • CSL Behring Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03473223
  • EudraCT 2017-000996-98
Other papers using this trial's data
  • ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial Journal of the American College of Cardiology, 2024-11-26 DOI, PubMed 39230545
  • Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial European heart journal, 2024-12-16 DOI, PubMed 39221651

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03473223. Randomized; quadruple masking; primary purpose prevention. Start 2018-03-21 (actual); primary completion 2023-02-16 (actual). Results posted on 2025-01-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Acronym
AEGIS-II
Condition
Acute Coronary Syndrome
Intervention (Biological)
Apolipoprotein A-I [human] (apoA-I)
Intervention (Other)
Placebo
Lead sponsor
CSL Behring (class: industry)

Record details

Record id
cardio:ct-nct03473223
Content hash
09e09775ea5c48486377f75161b13059a57364db27aa1c8c72518383e6f638bd